首创ATR抑制剂M6620单药或联合卡铂治疗晚期实体瘤的I期试验
这项I期试验评估了ATR抑制剂M6620(VX-970)单药(每周一次或两次)及联合卡铂方案(21天周期中卡铂第1天、M6620第2和第9天)在晚期实体瘤患者中的安全性、耐受性和最大耐受剂量,并探索药代动力学、抗肿瘤活性及药效动力学。40例患者入组,单药组17例安全耐受,推荐II期剂量(RP2D)为240 mg/m2;观察到RECISTv1.1完全缓解(转移性结直肠癌伴ATM缺失和ARID1A突变,无进展生存29个月)和部分缓解(铂类耐药、PARP抑制剂耐药的gBRCA1卵巢癌)等初步抗肿瘤活性,药效动力学显示CHK1磷酸化显著抑制。
要点
- M6620单药RP2D为240 mg/m2(每周一次或两次),安全耐受。
- 联合卡铂RP2D为M6620 90 mg/m2联合卡铂AUC5,需关注血液学毒性。
- 观察到RECISTv1.1完全缓解和部分缓解等初步抗肿瘤活性。
核心结论
- M6620作为首创ATR抑制剂单药及联合卡铂均耐受良好,并观察到靶点 engagement 和初步抗肿瘤应答。
研究设计与样本
- I期试验评估M6620单药(每周一次或两次)及联合卡铂方案(21天周期中卡铂第1天、M6620第2和第9天)在晚期实体瘤患者中的安全性、耐受性和最大耐受剂量。
主要发现
- 单药组安全耐受,RP2D为240 mg/m2(每周一次或两次)。
- 联合组出现机制相关血液学毒性需剂量延迟和减量,RP2D为M6620 90 mg/m2联合卡铂AUC5。
- 一例转移性结直肠癌伴ATM缺失和ARID1A突变患者达到RECISTv1.1完全缓解,无进展生存29个月。
- 一例晚期gBRCA1卵巢癌(铂类难治且PARP抑制剂耐药)达到RECISTv1.1部分缓解和GCIG CA125应答。
- 另有15例患者最佳应答为RECISTv1.1疾病稳定。
关键数值与推荐
- 单药RP2D:240 mg/m2(每周一次或两次)。
- 联合卡铂RP2D:M6620 90 mg/m2联合卡铂AUC5。
临床怎么用
- M6620单药及联合卡铂的RP2D已确定,可支持后续II期研究。
- 联合卡铂时需监测血液学毒性并做好剂量调整准备。
- 携带ATM缺失、ARID1A突变或gBRCA1等DNA修复缺陷的患者可能从M6620治疗中获益。
局限性
- 样本量小(共40例),为I期试验。
- 联合卡铂组较高剂量出现机制相关血液学毒性需剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin. PATIENTS AND METHODS: This phase I trial assessed the ATR inhibitor M6620 (VX-970) as monotherapy (once or twice weekly) and combined with carboplatin (carboplatin on day 1 and M6620 on days 2 and 9 in 21-day cycles). Primary objectives were safety, tolerability, and maximum tolerated dose; secondary objectives included pharmacokinetics and antitumor activity; exploratory objectives included pharmacodynamics in timed paired tumor biopsies. RESULTS: Forty patients were enrolled; 17 received M6620 monotherapy, which was safe and well tolerated. The recommended phase II dose (RP2D) for once- or twice-weekly administration was 240 mg/m2. A patient with metastatic colorectal cancer harboring molecular aberrations, including ATM loss and an ARID1A mutation, achieved RECISTv1.1 complete response and maintained this response, with a progression-free survival of 29 months at last assessment. Twenty-three patients received M6620 with carboplatin, with mechanism-based hematologic toxicities at higher doses, requiring dose delays and reductions. The RP2D for combination therapy was M6620 90 mg/m2 with carboplatin AUC5. A patient with advanced germline BRCA1 ovarian cancer achieved RECISTv1.1 partial response and Gynecologic Cancer Intergroup CA125 response despite being platinum refractory and PARP inhibitor resistant. An additional 15 patients had RECISTv1.1 stable disease as best response. Pharmacokinetics were dose proportional and exceeded preclinical efficacious levels. Pharmacodynamic studies demonstrated substantial inhibition of phosphorylation of CHK1, the downstream ATR substrate. CONCLUSION: To our knowledge, this report is the first of an ATR inhibitor as monotherapy and combined with carboplatin. M6620 was well tolerated, with target engagement and preliminary antitumor responses observed.
引用
- Yap TA, O'Carrigan B, Penney MS, et al. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020. PMID: 32568634. doi:10.1200/JCO.19.02404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。